LMR Partners’s SAB Biotherapeutics SABS Stock Holding History

LMR Partners’s Portfolio SABS Stock Details SABS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,085	Closed	-$109K	–	1263
2021 Q3	$109K	Buy	+1,085	New	+$108K	﹤0.01%	955

Other funds holding SABS

FPB

First PREMIER Bank Sioux Falls, South Dakota $619M AUM 20.21% 1-Year Est. Return

RCM

Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.33B AUM 1.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Shaolin Capital Management Miami, Florida $2.71B AUM 64.83% 1-Year Est. Return

IFAM

Institutional & Family Asset Management Fort Collins, Colorado $654M AUM 12.29% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Veritable Wilmington, Delaware $6.46B AUM 17.32% 1-Year Est. Return

LMR Partners's SABS Position: Q4 2021 in Review

LMR Partners sold out of SAB Biotherapeutics (SABS) in Q4 2021, closing a stake of 1,085 shares — an estimated $109K sold.

LMR Partners first reported a position in SABS in Q3 2021 and held it in 1 quarter. The position peaked at $109K in Q3 2021. 34 funds tracked by Wall St. Rank hold SABS as of Q4 2021.

LMR Partners reported no remaining SAB Biotherapeutics position as of Q4 2021 after selling out during the quarter.
LMR Partners sold 1,085 SAB Biotherapeutics shares in Q4 2021, an estimated $109K.
LMR Partners first reported a position in SAB Biotherapeutics in Q3 2021 and held it in 1 quarter.
LMR Partners's SAB Biotherapeutics position peaked at $109K in Q3 2021.
34 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q4 2021.

Based on LMR Partners's 13F filing for Q4 2021, filed 14 Feb 2022.